ClinicalTrials.gg
Not yet recruitingNCT07590167Updated May 15, 2026

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

A Phase 1 interventional study of AD-231 and AD-231A, AD-231D and AD-231C in Dyslipidemia and Hypertension, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Dyslipidemias by Yuhan Corporation — 5 open to participants now, 5 under way, 1 of them phase 3. Dyslipidemias · Yuhan Corporation.

Planned enrollment
6th of 11
60 · median 60
Started
2026
with 1 other
Phase 1
7 of 11
4 open now
Registered
11th of 11
by date

Among the 11 studies in Dyslipidemias by Yuhan Corporation, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 1, and was the 11th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

5 of the 11 studies in Dyslipidemias by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Dyslipidemias by Yuhan Corporation, or all of them as a file.
02

Study summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

03

Conditions studied

  • Dyslipidemia
  • Hypertension
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Sequence A (RT)

    Period 1: Reference Drug(AD-231A, AD-231D and AD-231C), Period 2 : Test Drug(AD-231)

    Drug: AD-231 · Drug: AD-231A, AD-231D and AD-231C

  • Experimental
    Sequence B (TR)

    Period 1: Test Drug(AD-231), Period 2 : Reference Drug(AD-231A, AD-231D and AD-231C)

    Drug: AD-231 · Drug: AD-231A, AD-231D and AD-231C

Interventions

  • DrugAD-231

    AD-231 Oral Tablet

  • DrugAD-231A, AD-231D and AD-231C

    AD-231A Oral Tablet + AD-231D Oral Tablet + AD-231C Oral Tablet

06

What researchers measure

Primary outcomes

  1. Maximum concentration of drug in plasma (Cmax)

    Cmax

    Time frame: pre-dose to 72 hours

  2. Area under the plasma concentration-time curve during dosing interval (AUCt)

    AUCt

    Time frame: pre-dose to 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jul 2026, 1 month later.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 1 month is below that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 15, 2026
StartEst.
Jun 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07590167
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
May 15, 2026

Study contacts

Dasom KIM
Contact
dskim@addpharma.co.kr
+82-31-891-5572

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion